Transplant Diagnostics Market Report Coverage:
Key Growth Factors & Challenges, Segmentation & Regional Outlook, Top Industry Trends & Opportunities, Competition Analysis, COVID-19 Impact Analysis & Projected Recovery, and Market Sizing & Forecast.
Latest launched research on Global
Transplant Diagnostics Market, it provides detailed analysis with presentable graphs, charts and tables. This report covers an in depth study of the Transplant Diagnostics Market size, growth, and share, trends, consumption, segments, application and Forecast 2027. With qualitative and quantitative analysis, we help you with thorough and comprehensive research on the global Transplant Diagnostics Market. This report has been prepared by experienced and knowledgeable market analysts and researchers. Each section of the research study is specially prepared to explore key aspects of the global Transplant Diagnostics Market. Buyers of the report will have access to accurate
Share this article
Share this article
ResearchAndMarkets.com s offering.
The scope of the report includes liquid biopsy technologies, applications, industry subsegments, biomarker technologies, major funding initiatives, patents and companies. The market sizes for liquid biopsy diagnostics are given for 2019, 2020 and 2025 (forecasted).
Liquid biopsy is creating a paradigm shift in medicine, and this is opening significant market opportunities. These market segments are particularly promising for the following liquid biopsy applications: noninvasive prenatal screening for average-risk populations; cancer screening and early detection; and recurrence monitoring for cancer patients.
Biomarker types of most interest include cell-free DNA (cfDNA), circulating tumor cells (CTCs) and exosomes. Ongoing advances in sensitive molecular technologies such as next-generation DNA sequencing (NGS) and digital polymerase chain reaction (dPCR) enable the detection of biomarkers that are present
The Factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving the growth of this market. However, the high instrument costs especially that of dPCR and the technical limitations of PCR have restricted their greater use.
qPCR reagents and consumables accounted for the largest share of qPCR market
Based on products & services, the market is categorized into reagents and consumables, instruments and software & services. The qPCR reagents and consumables segment is expected to command the largest share of the qPCR products & services market in 2020, owing to the factors such as the expanding applications of qPCR (owing to its technological benefits over traditional PCR, such as real-time analysis and reduced analysis time), growing privat
Digital PCR (dPCR) and Real-time PCR (qPCR) Market worth $7.6 billion by 2025 - Exclusive Report by MarketsandMarkets Digital PCR (dPCR) and Real-time PCR (qPCR) Market by Product (Instruments, Reagents & Consumables, Software & Services), Application (Clinical, Research, Forensic), End User (Hospitals & Diagnostic Centers, Pharma Biotech, CROs) - Global Forecast to 2025 , published by MarketsandMarkets, the dPCR and qPCR market is projected to reach USD 7.6 billion by 2025 from USD 4.9 billion in 2020, at a CAGR of 9.0% between 2020 and 2025.
Browse in-depth TOC on
253 - Tables
Download PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=174151204
The Factors such as the rising incidence of target infectious diseases and genetic disorders; technological advancements in PCR technologies; increasing investments, funds, and grants; increasing use of biomarker profiling for disease diagnostics; and successful completion of the Human Genome Project are driving
Parisa Khosropour Joins Advisory Board of Neuroenhancement Lab, Inc.
Share Article
Parisa Khosropour Joins the Advisory Board of Neuroenhancement Lab, Inc., a neuromodulation company first to develop technology for transplanting mental states™ from one person to another. We are very pleased to welcome Parisa to our advisory board,” said Dr. Alexander Poltorak, Neuroenhancement Lab’s Founder and President. “She brings a wealth of industry experience that will be of great value to our company.” SUFFERN, N.Y. (PRWEB) February 25, 2021 Neuroenhancement Lab, Inc., a neuromodulation company headquartered in Suffern, NY, announced today that Parisa Khosropour Joined its Advisory Board.
As a pioneer in neuromodulation, Neuroenhancement Lab is the first company to develop technology for transplanting mental state™ from one person to another.